When the cancer vaccine at any kind is absent, anti-PD-1 combined with anti-4-1BB is efficient to make a potent antitumor memory/effector T-cell response facing invasive tumor that makes it a suitable candidate for combination trials on patients (Chen et al., 2015[13]). This evidence concerns the gene TNFRSF9 and cancer.